Actionable news
0
All posts from Actionable news
Actionable news in FOMX: FOAMIX PHARMACEUTICALS Ltd. ORDINARY SHARES,

Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers

REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced that it will report top-line Phase 2 clinical study results of FDX-104 in acneiform rash associated with targeted antibody treatments and head and neck cancers on Thursday, December 3, and host a conference call and webcast with...


More